AC Immune SA
NASDAQ:ACIU

Watchlist Manager
AC Immune SA Logo
AC Immune SA
NASDAQ:ACIU
Watchlist
Price: 3.38 USD 2.74% Market Closed
Market Cap: 334.4m USD
Have any thoughts about
AC Immune SA?
Write Note

AC Immune SA
Effect of Foreign Exchange Rates

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

AC Immune SA
Effect of Foreign Exchange Rates Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Effect of Foreign Exchange Rates CAGR 3Y CAGR 5Y CAGR 10Y
AC Immune SA
NASDAQ:ACIU
Effect of Foreign Exchange Rates
-CHf5.1m
CAGR 3-Years
N/A
CAGR 5-Years
-69%
CAGR 10-Years
N/A
ADC Therapeutics SA
NYSE:ADCT
Effect of Foreign Exchange Rates
$184k
CAGR 3-Years
-8%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
CRISPR Therapeutics AG
NASDAQ:CRSP
Effect of Foreign Exchange Rates
$139k
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Molecular Partners AG
SIX:MOLN
Effect of Foreign Exchange Rates
-CHf2.4m
CAGR 3-Years
-31%
CAGR 5-Years
0%
CAGR 10-Years
N/A
Basilea Pharmaceutica AG
SIX:BSLN
Effect of Foreign Exchange Rates
-CHf30k
CAGR 3-Years
N/A
CAGR 5-Years
50%
CAGR 10-Years
11%
Kuros Biosciences AG
SIX:KURN
Effect of Foreign Exchange Rates
CHf12k
CAGR 3-Years
N/A
CAGR 5-Years
-45%
CAGR 10-Years
N/A
No Stocks Found

AC Immune SA
Glance View

Market Cap
335.3m USD
Industry
Biotechnology

AC Immune SA engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 143 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

ACIU Intrinsic Value
9.58 USD
Undervaluation 65%
Intrinsic Value
Price

See Also

What is AC Immune SA's Effect of Foreign Exchange Rates?
Effect of Foreign Exchange Rates
-5.1m CHF

Based on the financial report for Sep 30, 2024, AC Immune SA's Effect of Foreign Exchange Rates amounts to -5.1m CHF.

What is AC Immune SA's Effect of Foreign Exchange Rates growth rate?
Effect of Foreign Exchange Rates CAGR 5Y
-69%

Over the last year, the Effect of Foreign Exchange Rates growth was -1 375%.

Back to Top